Hauke Winter

Department Head / Prof. Dr. med

Heidelberg University

Germany

Research Interests

Explore related searches

Professors in Germany Professors in Cancer Biology Cancer Biology professors in Germany

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (5)

Philip Frederik Baum

GERMANY

View details

Thomas Muley

University Hospital Heidelberg

GERMANY

View details

Marc Schneider

Heidelberg University

GERMANY

View details

Moritz Jesinghaus

GERMANY

View details

Andreas Weigert

Associate Professor

Goethe University Frankfurt

GERMANY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Hauke Winter

Research Interests

Explore related searches

Contact this professor

Articles (10)

Comparison of the sensitivity of different criteria to select lung cancer patients for screening in a cohort of German patients.

Thoracic surgery in the non-intubated spontaneously breathing patient.

Multimodal therapy of epithelioid pleural mesothelioma: improved survival by changing the surgical treatment approach.

Fibrocytes boost tumor-supportive phenotypic switches in the lung cancer niche via the endothelin system.

Cellular dissociation grading on biopsies of pulmonary squamous cell carcinoma provides prognostic information across all stages and is congruent with resection specimen grading.

[Robot-assisted Thoracic Surgery: Learning Curve and Cost Analysis in a German High-Volume Centre].

Lung Adenocarcinoma Cell Sensitivity to Chemotherapies: A Spotlight on Lipid Droplets and <i>SREBF1</i> Gene.

Intratumoral Heterogeneity and Immune Modulation in Lung Adenocarcinoma in Female Smokers and Never Smokers.

Surgical Lung Biopsy for Interstitial Lung Disease: A Two Center Propensity Score Matching Analysis.

Major clinical benefit from adjuvant chemotherapy for stage II-III non-small cell lung cancer patients aged 75 years or older: a propensity score-matched analysis.

Collaborators (5)

Philip Frederik Baum

Thomas Muley

Marc Schneider

Moritz Jesinghaus

Andreas Weigert

Make your next move.